Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPV7 + tetanus peptide
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous Injection
01
Overview
LPV7 + tetanus peptide is an experimental cancer vaccine combination consisting of a long peptide vaccine (LPV7) and a synthetic helper T-cell epitope derived from the tetanus toxin. This combination is designed to enhance immune responses against melanoma by stimulating both CD8+ and CD4+ T cell responses. The LPV7 component contains multiple minimal epitope peptides (MEPs) targeting melanoma antigens, while the tetanus helper peptide acts as an immunological adjuvant to boost CD4+ T cell activation. In clinical trials, this combination has been administered with various adjuvants such as incomplete Freund's adjuvant (IFA), polyICLC (a TLR3 agonist), and resiquimod (a TLR7/8 agonist). The primary indication under investigation is resected stage II-IV melanoma. Early-phase studies have shown that the vaccine is safe and can induce both cellular and humoral immune responses in a subset of patients[2][3][4].
- Other names
- long peptide vaccine 7 plus tetanus helper peptideLPV7+Tet
02
Targets
MHC II (Major histocompatibility complex class II receptor)MHC I (MHC class I})
Beyond the preview
Go deeper on LPV7 + tetanus peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPV7 + tetanus peptide.